{"id":2518,"date":"2026-08-11T00:00:00","date_gmt":"2026-08-11T04:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2518"},"modified":"2026-08-13T02:27:21","modified_gmt":"2026-08-13T06:27:21","slug":"sl-325-phase-1-supports-longer-interval-dr3-blockade","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2518","title":{"rendered":"SL-325 Phase 1 Supports Longer-Interval DR3 Blockade"},"content":{"rendered":"

Company:<\/strong> Shattuck Labs · Event Type:<\/strong> Clinical\/Regulatory Signal · Product\/Asset:<\/strong> SL-325 · Subject:<\/strong> Inflammatory Disease · Event Date:<\/strong> August 11, 2026<\/p>\n

\"SL-325<\/p>\n

Summary<\/h4>\n

Shattuck Labs reported Phase 1 healthy-volunteer results for SL-325, a monoclonal antibody that blocks the TL1A receptor DR3. The company observed 3.7% anti-drug-antibody incidence and complete blockade of TL1A binding to DR3 for more than three months at doses of at least 1 mg\/kg, supporting a possible quarterly maintenance schedule. The signal is positive\/uncertain and validates pharmacology, but it does not establish efficacy in Crohn’s disease. The registered Phase 1 study had no posted results at the cutoff, so the evidence remains company-reported.<\/p>\n

What Happened<\/h4>\n

The Phase 1 program enrolled healthy volunteers and evaluated safety, pharmacokinetics, pharmacodynamics and immunogenicity. Shattuck described the safety profile as consistent with the TL1A class, with no evidence of DR3 agonism. The company plans to initiate the randomized, double-blind, placebo-controlled Phase 2b RECEPTIVE-CD1 study in the third quarter of 2026. That study is designed to enroll approximately 232 patients with Crohn’s disease, test three dose levels and assess endoscopic response at week 12, with data expected in the first half of 2028. Cash and investments of approximately $208.3 million were projected to fund operations into 2029.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation 1 \u2014 directly blocking DR3 may produce durable pathway suppression with less frequent dosing and low immunogenicity. Supporting evidence includes multi-month receptor blockade and 3.7% anti-drug-antibody incidence in the disclosed healthy-volunteer dataset. Contradicting evidence is that pharmacodynamic duration does not guarantee mucosal efficacy, and a low immunogenicity rate in a small early study may change with repeat dosing in inflammatory disease.<\/p>\n

Interpretation 2 \u2014 differentiation from antibodies that neutralize TL1A remains unproven. Supporting evidence includes receptor-level blockade and the absence of detected agonism, which may reduce dependence on ligand concentration. Contradicting evidence includes a competitive clinical field, no active comparator, no Crohn’s tissue or endoscopic data and no proof that longer intervals improve adherence or outcomes.<\/p>\n

Evidence that would upgrade the interpretation includes dose-related endoscopic and clinical remission, durable maintenance benefit, low immunogenicity after repeated dosing and biomarker evidence of tissue-level pathway suppression. Evidence that would downgrade it includes dose-response failure, anti-drug antibodies, receptor agonism, infection or immune toxicity. A randomized Phase 2b study without meaningful endoscopic improvement would falsify the current disease-efficacy thesis.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Verified facts:<\/strong> same-day SEC-filed earnings exhibit; company-reported 3.7% anti-drug-antibody incidence; complete TL1A-binding blockade for more than three months at doses at or above 1 mg\/kg; Phase 2b initiation planned for the third quarter; approximately $208.3 million cash and investments.<\/li>\n
  • Company claim:<\/strong> the profile may be best in mechanism and support quarterly maintenance.<\/li>\n
  • Independent corroboration:<\/strong> the registry confirms a 72-participant healthy-volunteer Phase 1 design but had no results posted.<\/li>\n
  • Missing facts:<\/strong> denominators by dose, full adverse-event table, confidence intervals, assay thresholds, repeat-dose immunogenicity, Crohn’s tissue pharmacodynamics and regulatory agreement on Phase 2b dosing.<\/li>\n<\/ul>\n

    Insilens Take<\/h4>\n

    SL-325 has cleared a necessary pharmacology hurdle: sustained receptor occupancy or functional blockade without an obvious early immunogenicity problem. It has not cleared the central translational hurdle of improving intestinal inflammation. The program should be judged on prospectively randomized endoscopic outcomes and repeat-dose safety, not on healthy-volunteer pharmacokinetics or the company’s best-in-mechanism language.<\/p>\n

    Company and Product Background<\/h4>\n

    TL1A is a cytokine linked to intestinal inflammation and fibrosis. It signals through death receptor 3, or DR3, on immune cells and is genetically and clinically implicated in inflammatory bowel disease. Most competing programs neutralize TL1A itself. SL-325 instead targets DR3 to block ligand binding. The approach could provide durable pathway suppression, but receptor biology raises a specific need to exclude agonistic signaling and confirm that systemic blockade is safe during chronic treatment.<\/p>\n

    Importance and Confidence<\/h4>\n

    Signal Importance: 3\/5. Signal Direction: positive\/uncertain. Confidence in Facts: high. Confidence in Interpretation: medium. Red-team check: the title describes longer-interval pharmacology rather than Crohn’s efficacy, and the report explicitly rejects best-in-mechanism and quarterly-dosing claims as unproven until repeat-dose patient data are available.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Shattuck Labs reported Phase 1 healthy-volunteer results for SL-325, a monoclonal antibody that blocks the TL1A receptor DR3. The company observed 3.7% anti-drug-antibody incidence and complete blockade of TL1A binding to DR3 for more…<\/p>\n","protected":false},"author":5,"featured_media":2517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[325,324],"class_list":["post-2518","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-inflammatory-disease","tag-shattuck-labs"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2518"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2518\/revisions"}],"predecessor-version":[{"id":2519,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2518\/revisions\/2519"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2517"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}